We collect cookies to analyze our website traffic and performance; we never collect any personal data. Cookie Policy
Accept
NEW YORK DAWN™NEW YORK DAWN™NEW YORK DAWN™
Notification Show More
Font ResizerAa
  • Home
  • Trending
  • New York
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
  • Crypto & NFTs
  • Tech
  • Lifestyle
    • Lifestyle
    • Food
    • Travel
    • Fashion
    • Art
  • Health
  • Sports
  • Entertainment
Reading: New remedy could delay most cancers in high-risk myeloma
Share
Font ResizerAa
NEW YORK DAWN™NEW YORK DAWN™
Search
  • Home
  • Trending
  • New York
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
  • Crypto & NFTs
  • Tech
  • Lifestyle
    • Lifestyle
    • Food
    • Travel
    • Fashion
    • Art
  • Health
  • Sports
  • Entertainment
Follow US
NEW YORK DAWN™ > Blog > Health > New remedy could delay most cancers in high-risk myeloma
New remedy could delay most cancers in high-risk myeloma
Health

New remedy could delay most cancers in high-risk myeloma

Last updated: December 11, 2024 7:32 am
Editorial Board Published December 11, 2024
Share
SHARE

Credit score: Mayo Clinic

A brand new remedy is displaying promise for individuals with high-risk smoldering a number of myeloma (SMM). This precancerous situation can progress to lively a number of myeloma, a kind of blood most cancers. Excessive-risk SMM carries the next chance of development.

Outcomes from a section 3 scientific trial, revealed within the New England Journal of Medication and offered at this week’s American Society of Hematology assembly, demonstrated that daratumumab, a monoclonal antibody that targets CD38, a protein discovered on the floor of myeloma cells, considerably reduces the danger of development to lively a number of myeloma and improves general survival in comparison with lively monitoring.

Smoldering a number of myeloma is a situation through which irregular plasma cells accumulate within the bone marrow however don’t show signs of lively a number of myeloma. Excessive-risk SMM, nevertheless, carries a big danger of progressing to lively illness. Till now, there was no authorized remedy for this high-risk group.

The multicenter, worldwide AQUILA research randomly assigned 390 sufferers with high-risk SMM to obtain both daratumumab or lively monitoring. After a median follow-up of 65.2 months, the research demonstrated a 51% discount within the danger of illness development or loss of life for these receiving daratumumab. At 5 years, 63.1% of sufferers within the daratumumab group remained progression-free, in comparison with 40.8% within the lively monitoring group. Survival at 5 years was additionally considerably larger within the daratumumab group (93% vs. 86.9%).

“These results are a major advancement in the treatment of high-risk smoldering multiple myeloma,” says S. Vincent Rajkumar, M.D., hematologist, Mayo Clinic Complete Most cancers Middle and lead investigator of the trial.

“For the first time, we have a treatment option that can significantly delay or prevent the progression to active disease, improving the lives of patients and offering them a chance at a longer, healthier future.”

Whereas hypertension was the commonest aspect impact, occurring in a small share of sufferers in each teams, no new security considerations had been recognized with daratumumab.

“This study provides strong evidence for the use of daratumumab as a treatment for high-risk smoldering multiple myeloma,” says Dr. Rajkumar, the Edward W. and Betty Knight Scripps Professor of Medication in honor of Edward C. Rosenow III, M.D.

Sufferers ought to talk about this new remedy possibility with their well being care crew to find out whether it is applicable for his or her particular person circumstances.

Extra info:
Meletios A. Dimopoulos et al, Daratumumab or Lively Monitoring for Excessive-Threat Smoldering A number of Myeloma, New England Journal of Medication (2024). DOI: 10.1056/NEJMoa2409029

Quotation:
New remedy could delay most cancers in high-risk myeloma (2024, December 10)
retrieved 11 December 2024
from https://medicalxpress.com/information/2024-12-treatment-delay-cancer-high-myeloma.html

This doc is topic to copyright. Aside from any truthful dealing for the aim of personal research or analysis, no
half could also be reproduced with out the written permission. The content material is offered for info functions solely.

You Might Also Like

How relative efficiency suggestions can encourage docs

Mind connections at 3 months predict toddler emotional growth

Tips issued for surgical administration of power rhinosinusitis in adults

Opinion: Aggressive on-line child formulation campaigns should finish

FDA points highest alert over tomato recall in 3 southern states

TAGGED:Cancerdelayhighriskmyelomatreatment
Share This Article
Facebook Twitter Email Print

Follow US

Find US on Social Medias
FacebookLike
TwitterFollow
YoutubeSubscribe
TelegramFollow
Popular News
Big Tech Is Proving Resilient as the Economy Cools
Technology

Big Tech Is Proving Resilient as the Economy Cools

Editorial Board July 28, 2022
LIFE WITHOUT CAP: Knicks studying to regulate, compete with Jalen Brunson out resulting from damage
Cookie Monster, Massive Chook and Elmo want new ‘Sesame Road’ tackle
Cloth Masks Do Not Protect Against Virus as Effectively as Others, C.D.C. Says
Yankees land nearer Devin Williams in commerce with Brewers, ship out Nestor Cortes, Caleb Durbin

You Might Also Like

Research: Pre-operative THP results in pCR in 64% of early-stage HER2+ ER- breast most cancers sufferers
Health

Research: Pre-operative THP results in pCR in 64% of early-stage HER2+ ER- breast most cancers sufferers

June 3, 2025
Consuming more healthy can defend growing older mind
Health

Consuming more healthy can defend growing older mind

June 2, 2025
ASCO: Vepdegestrant ups survival in ER+, HER2− superior breast most cancers with ESR1 mutations
Health

ASCO: Vepdegestrant ups survival in ER+, HER2− superior breast most cancers with ESR1 mutations

June 2, 2025
Antibody-drug conjugate reveals promising security and response charges for sufferers with uncommon blood most cancers
Health

Antibody-drug conjugate reveals promising security and response charges for sufferers with uncommon blood most cancers

June 2, 2025

Categories

  • Health
  • Sports
  • Politics
  • Entertainment
  • Technology
  • World
  • Art

About US

New York Dawn is a proud and integral publication of the Enspirers News Group, embodying the values of journalistic integrity and excellence.
Company
  • About Us
  • Newsroom Policies & Standards
  • Diversity & Inclusion
  • Careers
  • Media & Community Relations
  • Accessibility Statement
Contact Us
  • Contact Us
  • Contact Customer Care
  • Advertise
  • Licensing & Syndication
  • Request a Correction
  • Contact the Newsroom
  • Send a News Tip
  • Report a Vulnerability
Term of Use
  • Digital Products Terms of Sale
  • Terms of Service
  • Privacy Policy
  • Cookie Settings
  • Submissions & Discussion Policy
  • RSS Terms of Service
  • Ad Choices
© 2024 New York Dawn. All Rights Reserved.
Welcome Back!

Sign in to your account

Lost your password?